Since Ganymed unveiled the efficacy data of Zolbetuximab (IMAB362), the anti-Claudin18.2 monoclonal antibody, for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJ) at the 2016 ASCO conference, Claudin18.2 has emerged as a focal point for pharmaceutical companies eager to advance therapeutic options. These companies explore various technological routes, including monoclonal antibodies, bispecific antibodies, […]
When it comes to DLL3, people immediately think of Rova-T, the ADC drug targeting the DLL3 receptor that dashed AbbVie’s $5.8 billion expectations. AbbVie’s setback had once caused a decline in the enthusiasm for DLL3-targeted treatments. However, the spotlight returned when Amgen unveiled the DLL3/CD3 bispecific antibody Tarlatamab data at the 2023 ESMO conference. On […]
On December 7, 2023, AbelZeta announced a collaboration with AstraZeneca to jointly develop C-CAR031, a chimeric antigen receptor T-cell (CAR-T) therapy targeting Glypican-3 (GPC3) for hepatocellular carcinoma (HCC). According to the agreement, AbelZeta is eligible for milestone payments and licensing fees for its global development. The drug will be exclusively developed, manufactured, and commercialized by […]
GPRC5D, identified as a G protein-coupled orphan receptor, demonstrates limited expression in normal tissues.
The 5T4 protein, also known as Wnt-activated inhibitory factor 1 (WAIF1) or Trophoblast Glycoprotein (TPBG), is a glycoprotein found in embryonic trophoblast cells. It has been identified as a treatment target for solid tumors due to its abundance in cancerous tissues and limited expression in normal tissues. Currently, there are approximately nine investigational drugs targeting […]
In June 2023, BioNTech presented the first human trial data of BNT211 at the American Society of Clinical Oncology (ASCO). BNT211 is a CLDN-6-targeting CAR-T cell therapy in combination with a CLDN6-encoding mRNA vaccine (CARVac). mRNA vaccines stimulate the expansion of CAR-T cells in the patients’ body by inducing the expression of CLDN6 on the surface of antigen-presenting cells, […]
In 2023…… On May 12th, LaNova announced that AstraZeneca will receive an exclusive global license for LM-305’s research, development, and commercialization. LM-305 is a new pre-clinical stage antibody-drug conjugate (ADC) targeting GPRC5D. LaNova Medicines will receive an immediate payment of $55 million and $545 million in additional development and commercial milestone payments. On May 19th, the clinical trial application for OriCAR-017 […]